Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Roivant Sciences Ltd. (ROIV : NSDQ)

• Company Description    Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK. Number of Employees: 721

• Price / Volume Information    Yesterday's Closing Price: $35.01 Daily Weekly Monthly 20 Day Moving Average: 4,997,268 shares Shares Outstanding: 719.27 (millions) Market Capitalization: $25,181.64 (millions) Beta: 1.11 52 Week High: $37.00 52 Week Low: $10.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.91% 2.15% 12 Week 22.71% 19.35% Year To Date 61.34% 49.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7th Floor 50 Broadway - LONDON,X0 SW1H 0DB GBR ph: 44-20-7400-3347 fax: - keyur.parekh@roivant.com https://roivant.com

• General Corporate Information    Officers Matthew Gline - Chief Executive Officer and Director Mayukh Sukhatme - President and Chief Investment Officer Richard Pulik - Chief Financial Officer Jennifer Humes - Chief Accounting Officer Keith Manchester - Director Peer Information Roivant Sciences Ltd. (CORR.) Roivant Sciences Ltd. (RSPI) Roivant Sciences Ltd. (CGXP) Roivant Sciences Ltd. (BGEN) Roivant Sciences Ltd. (GTBP) Roivant Sciences Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G76279101 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 719.27 Most Recent Split Date: (:1) Beta: 1.11 Market Capitalization: $25,181.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.47 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 40.40% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.77 Price/Cash Flow: - Price / Sales: 3,048.62 EPS Growth vs. Year Ago Period: -48.39% vs. Previous Quarter: -27.78% Sales Growth vs. Year Ago Period: -66.71% vs. Previous Quarter: 26.06% ROE 06/30/26 - - 03/31/26 - -20.54 12/31/25 - -19.04 ROA 06/30/26 - - 03/31/26 - -19.43 12/31/25 - -18.15 Current Ratio 06/30/26 - - 03/31/26 - 18.37 12/31/25 - 30.66 Quick Ratio 06/30/26 - - 03/31/26 - 18.37 12/31/25 - 30.66 Operating Margin 06/30/26 - - 03/31/26 - -12,365.73 12/31/25 - -7,076.27 Net Margin 06/30/26 - - 03/31/26 - -3,629.19 12/31/25 - -6,079.94 Pre-Tax Margin 06/30/26 - - 03/31/26 - -3,203.12 12/31/25 - -6,925.09 Book Value 06/30/26 - - 03/31/26 - 7.35 12/31/25 - 7.01 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©